Indaptus Therapeutics, Inc.

$INDP announced a $6M strategic investment led by @ActivistLazar who has been appointed Co-CEO and Chairman of the Board. This transaction strengthens our balance sheet while we explore the next chapter of the business to drive shareholder value. Read more: bit.ly/4phKK07

Our CSO, Michael Newman, PhD, presents this week at the Donor Selection & Cell Source Summit in San Diego, sharing how our Decoy platform could help tackle one of the toughest challenges in allogeneic cell therapy: donor cell variability. $INDP #celltherapy

Our CSO, Michael Newman, presenting new Decoy20 data at #CICON25 last week. Highlights: - Activation of multiple immune cell types in vitro - New findings: Decoy induces anti-tumor M1 macrophages + gamma-delta T cells Exciting progress as we advance our clinical program! $INDP #Immunotherapy #CancerResearch

Q2 wrap-up: · $5.7M financing · First patient dosed in Decoy20 + TEVIMBRA® combo trial CFO Nir Sassi explains why this could be Indaptus’ most exciting phase yet! $INDP #biotech #immunotherapy #cancerresearch

Today marks 4 years since we launched Indaptus. In that time, with just a small, focused team, we’ve: • Raised an initial $30M and listed on Nasdaq • Filed our IND • Completed Phase 1 safety (single and weekly dosing) • Launched a Ph1b/2 combo with @BeOneMedicines • Expanded our IP + pipeline with applications beyond oncology • Stayed lean and executed in a brutal funding environment for biotech None of this happens without our long-term investors, partners, and 20+ years of work by our CSO, Dr. Michael Newman. We’re proud of how far we’ve come, and excited to share initial combo data soon. #biotech #immunotherapy $INDP

Check out our new video with Bob Martell, Indaptus Board member, explaining how #Decoy20 stands out by activating both innate & adaptive immune systems—potentially unlocking new possibilities in cancer therapy. $INDP #CancerResearch #Immunotherapy #Biotech #LiverCancer

Our CEO, Jeffrey Meckler, will speak at #BIO2025 in Boston on June 16! Please stop by and attend the panel: “Who Are Today’s Biotech Underdogs and What Will It Take to Succeed?” •1:45–2:45PM •Room 252AB $INDP #Biotech #Immunotherapy #CancerResearch #Decoy20

Excited to announce we just dosed the first patient in our combo trial of Decoy20 + PD-1 checkpoint inhibitor tislelizumab! This Phase 1b/2 study targets patients with tumors that have resisted or stopped responding to immunotherapy, and marks the first clinical test of our Decoy platform in combination with another agent. More updates to come… $INDP #Immunotherapy #Decoy20 #CheckpointInhibitor indaptusrx.com/investors/news…

Proud to share that our Founder & CSO, Dr. Michael Newman, will speak at and chair Day 2 at HansonWade’s Cytokine-Based Drug Development Summit (May 15–16) in Boston. He’ll present on pulsed cytokine delivery & our Decoy platform’s approach to immune activation. $INDP #Immunotherapy #Cytokines #Decoy20 indaptusrx.com/investors/news…

Just wrapped a great week of investor meetings across Europe. Despite tough markets, interest in our story has been fantastic. Unlike most cancer therapies that target just one pathway, Decoy20 safely activates the entire immune system — both innate & adaptive. Investors are recognizing its huge potential, esp. in combo to boost the effectiveness of other treatments. $INDP #Biotech #CancerResearch #Immunotherapy #Decoy20

How are side effects of Decoy20 managed? In our latest video, CMO Roger Waltzman explains how #Decoy20 typically causes mild, short-lived symptoms and how we manage them with IV fluids & over-the-counter meds to ensure patients can comfortably continue treatment. $INDP #CancerCare #Immunotherapy #Biotech #LungCancer

Thanks @GENbio for spotlighting our work at Indaptus alongside other pioneers in NK cell and innate immunity research. We've since launched our first combo study of #Decoy20 with @BeOneMedicines' PD-1 inhibitor, and continue to push forward the next wave of immunotherapy. #CancerResearch #Immunotherapy #NKcells #CheckpointInhibitors #biotech $INDP genengnews.com/topics/cancer/…

CEO Jeffrey Meckler shares thoughts on launch of Phase 1b/2 trial combining Decoy20 with tiselizumab (BeiGene's anti PD-1). Investor meetings have been incredibly positive, and we're eager to provide further updates as the year unfolds... $INDP

New data from our Decoy20 trial! Findings strongly support immune activation as designed, with biomarkers showing clear signs of immune cell trafficking—a key factor in cancer immunotherapy. More updates to come as we advance the trial! $INDP #Biotech #CancerResearch #Immunotherapy #ClinicalTrials #Decoy20 indaptusrx.com/investors/news…

Big milestone! We’ve launched the next phase of our Phase 1b/2 trial, combining Decoy20 with BeiGene’s PD-1 inhibitor, tislelizumab. A key step in testing its potential to enhance checkpoint inhibitors in solid tumors. Stay tuned for more… indaptusrx.com/investors/news… $INDP #Biotech #CancerResearch #Immunotherapy #Decoy20

Our CFO, Nir Sassi, breaks down the key highlights from our latest earnings release, including clinical progress, financial updates, and what’s ahead for Indaptus in 2025. Watch the full recap here! $INDP #Biotech #ClinicalTrials #CancerResearch #Decoy20 #IndaptusTherapeutics

Pleased to report Q4 and FY2024 earnings, and the latest milestone in our Phase 1 trial of Decoy20: •20th patient enrolled in weekly dosing cohort •Immune activation & pharmacokinetics exceeding expectations •Early signs of benefit with some patients showing stable disease Excited to advance toward our Decoy20 + BeiGene PD-1 combo trial! Read the full release here: indaptusrx.com/investors/news… $INDP #Biotech #CancerResearch #ClinicalTrials #Immunotherapy #Decoy20

Our CEO joined the Empowered Patient Podcast to discuss how our Decoy platform is designed to activate the immune system in the fight against cancer and viral infections—balancing efficacy with safety, and potentially enhancing existing treatments. Listen here: empoweredpatientradio.com/pulse-prime-ap… $INDP #Immunotherapy #CancerResearch #Biotech #Decoy20

Proud to announce @GovCanHealth has authorized the launch of #Decoy20 clinical trials at Canadian sites! This expansion strengthens patient recruitment and clinical data diversity as we work to advance innovative new treatments for cancer. $INDP #Biotech #ClinicalTrials #CancerResearch #Immunotherapy #HealthCanada indaptusrx.com/investors/news…

In our latest video, CEO Jeffrey Meckler addresses a key investor question: When will we see efficacy data for #Decoy20? Our Phase 1 trial is focused on safety, but we’re hopeful meaningful efficacy results will follow soon. Watch the full video for more... $INDP #CancerResearch #Biotech #Immunotherapy #ClinicalTrials #ColonCancer